Jupiter Neurosciences, Inc. Announces Reverse Stock Split

Jupiter Neurosciences Raises Capital Through Equity Offering

Jupiter Neurosciences Sells 11,470,000 Shares to Yorkville for About $3.6 Million in Unregistered Offering

Jupiter Neurosciences Held Annual Shareholder Meeting, with 59% of Shares Represented

Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences

Jupiter Neurosciences Director Andrew Jon Cutler Files Initial Beneficial Ownership Statement

Jupiter Neurosciences Licenses ALA-002 for U.S. Development

Jupiter Neurosciences Stock (JUNS) Jumps on a New License Deal

Jupiter Neurosciences (nasdaq: Juns) Signs Definitive Agreement for Exclusive U.S. Rights to Ala-002 in Transaction Valued at up to $100 Million

Jupiter Neurosciences - Royalty of 3% of Net Sales After Third Commercialization Milestone

Jupiter Neurosciences - Deal Valued at up to $100 Mln Including Milestone Payments

Pharmala Licenses Exclusive US Rights to Ala-002 to Jupiter Neurosciences for up to Us$100 Million

Pharmala Biotech - to Manufacture Gmp-grade Ala-002 for Jupiter Under Separate Supply Agreement

Pharmala Biotech - Development and Regulatory Milestones up to $23.33 Mln Including $20 Mln for FDA Approval

Pharmala Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to Ala-002

Pharmala Biotech - Upfront Payment of $3.33 Mln: $1.50 Mln Cash, $1.83 Mln in Jupiter Stock

Pharmala Biotech - Deal Valued up to $100 Mln Including $3.33 Mln Upfront and Milestones Plus Royalties

Pharmala Biotech - to Receive 3% Royalty on U.S. Net Sales After Third Milestone

Jupiter Neurosciences Names Former White House Economic Adviser Tomas Philipson to Board

Jupiter Neurosciences Strengthens Board with Appointment of DR. Tomas J. Philipson